3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Timing and Predictors of Loss of Infectivity Among Healthcare Workers With Mild Primary and Recurrent COVID-19: A Prospective Observational Cohort Study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          There is a need to understand the duration of infectivity of primary and recurrent coronavirus disease 2019 (COVID-19) and identify predictors of loss of infectivity.

          Methods

          Prospective observational cohort study with serial viral culture, rapid antigen detection test (RADT) and reverse transcription polymerase chain reaction (RT-PCR) on nasopharyngeal specimens of healthcare workers with COVID-19. The primary outcome was viral culture positivity as indicative of infectivity. Predictors of loss of infectivity were determined using multivariate regression model. The performance of the US Centers for Disease Control and Prevention (CDC) criteria (fever resolution, symptom improvement, and negative RADT) to predict loss of infectivity was also investigated.

          Results

          In total, 121 participants (91 female [79.3%]; average age, 40 years) were enrolled. Most (n = 107, 88.4%) had received ≥3 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine doses, and 20 (16.5%) had COVID-19 previously. Viral culture positivity decreased from 71.9% (87/121) on day 5 of infection to 18.2% (22/121) on day 10. Participants with recurrent COVID-19 had a lower likelihood of infectivity than those with primary COVID-19 at each follow-up (day 5 odds ratio [OR], 0.14; P < .001]; day 7 OR, 0.04; P = .003]) and were all non-infective by day 10 ( P = .02). Independent predictors of infectivity included prior COVID-19 (adjusted OR [aOR] on day 5, 0.005; P = .003), an RT-PCR cycle threshold [Ct] value <23 (aOR on day 5, 22.75; P < .001) but not symptom improvement or RADT result.

          The CDC criteria would identify 36% (24/67) of all non-infectious individuals on day 7. However, 17% (5/29) of those meeting all the criteria had a positive viral culture.

          Conclusions

          Infectivity of recurrent COVID-19 is shorter than primary infections. Loss of infectivity algorithms could be optimized.

          Abstract

          Among 121 individuals with COVID-19, viral culture positivity decreased from 72% on day 5 of infection to 18% on day 10. Predictors of loss of infectivity included a history of previous infection and a RT-PCR cycle threshold value >27.

          Graphical Abstract

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          Virological assessment of hospitalized patients with COVID-2019

          Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in late 20191,2. Initial outbreaks in China involved 13.8% of cases with severe courses, and 6.1% of cases with critical courses3. This severe presentation may result from the virus using a virus receptor that is expressed predominantly in the lung2,4; the same receptor tropism is thought to have determined the pathogenicity-but also aided in the control-of severe acute respiratory syndrome (SARS) in 20035. However, there are reports of cases of COVID-19 in which the patient shows mild upper respiratory tract symptoms, which suggests the potential for pre- or oligosymptomatic transmission6-8. There is an urgent need for information on virus replication, immunity and infectivity in specific sites of the body. Here we report a detailed virological analysis of nine cases of COVID-19 that provides proof of active virus replication in tissues of the upper respiratory tract. Pharyngeal virus shedding was very high during the first week of symptoms, with a peak at 7.11 × 108 RNA copies per throat swab on day 4. Infectious virus was readily isolated from samples derived from the throat or lung, but not from stool samples-in spite of high concentrations of virus RNA. Blood and urine samples never yielded virus. Active replication in the throat was confirmed by the presence of viral replicative RNA intermediates in the throat samples. We consistently detected sequence-distinct virus populations in throat and lung samples from one patient, proving independent replication. The shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7 days in 50% of patients (and by day 14 in all patients), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild illness of the upper respiratory tract. The confirmation of active virus replication in the upper respiratory tract has implications for the containment of COVID-19.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

            Much of biomedical research is observational. The reporting of such research is often inadequate, which hampers the assessment of its strengths and weaknesses and of a study's generalizability. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Initiative developed recommendations on what should be included in an accurate and complete report of an observational study. We defined the scope of the recommendations to cover three main study designs: cohort, case-control, and cross-sectional studies. We convened a 2-day workshop in September 2004, with methodologists, researchers, and journal editors to draft a checklist of items. This list was subsequently revised during several meetings of the coordinating group and in e-mail discussions with the larger group of STROBE contributors, taking into account empirical evidence and methodological considerations. The workshop and the subsequent iterative process of consultation and revision resulted in a checklist of 22 items (the STROBE Statement) that relate to the title, abstract, introduction, methods, results, and discussion sections of articles. Eighteen items are common to all three study designs and four are specific for cohort, case-control, or cross-sectional studies. A detailed Explanation and Elaboration document is published separately and is freely available on the web sites of PLoS Medicine, Annals of Internal Medicine, and Epidemiology. We hope that the STROBE Statement will contribute to improving the quality of reporting of observational studies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility

              Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can spread rapidly within skilled nursing facilities. After identification of a case of Covid-19 in a skilled nursing facility, we assessed transmission and evaluated the adequacy of symptom-based screening to identify infections in residents. Methods We conducted two serial point-prevalence surveys, 1 week apart, in which assenting residents of the facility underwent nasopharyngeal and oropharyngeal testing for SARS-CoV-2, including real-time reverse-transcriptase polymerase chain reaction (rRT-PCR), viral culture, and sequencing. Symptoms that had been present during the preceding 14 days were recorded. Asymptomatic residents who tested positive were reassessed 7 days later. Residents with SARS-CoV-2 infection were categorized as symptomatic with typical symptoms (fever, cough, or shortness of breath), symptomatic with only atypical symptoms, presymptomatic, or asymptomatic. Results Twenty-three days after the first positive test result in a resident at this skilled nursing facility, 57 of 89 residents (64%) tested positive for SARS-CoV-2. Among 76 residents who participated in point-prevalence surveys, 48 (63%) tested positive. Of these 48 residents, 27 (56%) were asymptomatic at the time of testing; 24 subsequently developed symptoms (median time to onset, 4 days). Samples from these 24 presymptomatic residents had a median rRT-PCR cycle threshold value of 23.1, and viable virus was recovered from 17 residents. As of April 3, of the 57 residents with SARS-CoV-2 infection, 11 had been hospitalized (3 in the intensive care unit) and 15 had died (mortality, 26%). Of the 34 residents whose specimens were sequenced, 27 (79%) had sequences that fit into two clusters with a difference of one nucleotide. Conclusions Rapid and widespread transmission of SARS-CoV-2 was demonstrated in this skilled nursing facility. More than half of residents with positive test results were asymptomatic at the time of testing and most likely contributed to transmission. Infection-control strategies focused solely on symptomatic residents were not sufficient to prevent transmission after SARS-CoV-2 introduction into this facility.
                Bookmark

                Author and article information

                Contributors
                Journal
                Clin Infect Dis
                Clin Infect Dis
                cid
                Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
                Oxford University Press (US )
                1058-4838
                1537-6591
                15 March 2024
                07 September 2023
                07 September 2023
                : 78
                : 3
                : 613-624
                Affiliations
                McGill University Faculty of Medicine , Montréal, Canada
                Faculté de médecine, Université de Montréal , Montréal, Canada
                Laboratoire de Santé Publique du Québec , Sainte-Anne-de-Bellevue, Canada
                Institut National de Santé Publique du Québec , Québec City, Canada
                Laboratoire de Santé Publique du Québec , Sainte-Anne-de-Bellevue, Canada
                Institut National de Santé Publique du Québec , Québec City, Canada
                Laboratoire de Santé Publique du Québec , Sainte-Anne-de-Bellevue, Canada
                Institut National de Santé Publique du Québec , Québec City, Canada
                Institut National de Santé Publique du Québec , Québec City, Canada
                Université Laval , Québec City, Canada
                Laboratoire de Santé Publique du Québec , Sainte-Anne-de-Bellevue, Canada
                Institut National de Santé Publique du Québec , Québec City, Canada
                CHU de Québec—Université Laval , Québec City, Canada
                McGill University Faculty of Medicine , Montréal, Canada
                Jewish General Hospital Sir Mortimer B. Davis , Montréal, Canada
                Laboratoire de Santé Publique du Québec , Sainte-Anne-de-Bellevue, Canada
                Institut National de Santé Publique du Québec , Québec City, Canada
                Institut National de Santé Publique du Québec , Québec City, Canada
                Faculté de médecine, Université de Montréal , Montréal, Canada
                Centre Hospitalier de l’Université de Montréal (CHUM) and CHUM Research Center , Montréal, Canada
                Université Laval , Québec City, Canada
                Institut National de Santé Publique du Québec , Québec City, Canada
                Université Laval , Québec City, Canada
                McGill University Faculty of Medicine , Montréal, Canada
                Jewish General Hospital Sir Mortimer B. Davis , Montréal, Canada
                Lady Davis Research Institute , Montréal, Canada
                Author notes
                Correspondence: Y. Longtin, Jewish General Hospital—SMBD, 3755 Chemin de la Côte-Sainte-Catherine, Montréal, Québec H3T 1E2, Canada ( yves.longtin@ 123456mcgill.ca ).
                Correspondence: G. De Serres, Institut National de Santé Publique du Québec, 2400 avenue d’Estimauville, Québec, QC G1E 7G9, Canada ( Gaston.DeSerres@ 123456inspq.qc.ca ).

                Potential conflicts of interest. Y. L. reports receiving research support from Summit (Oxford) and a role as member of council for Association for Medical Microbiology and Infectious Diseases Canada. J. C. reports 2021-06-01 to 2022-05-31 | Grant Canadian Institutes of Health Research (Ottawa, CA), URL: https://app.dimensions.ai/details/grant/grant.9982867 Grant_number: COVID19 persistent symptomatology: an investigation of the metabolomic and proteomic underpinning ad31226d181b8382df84496de244efd5. P. S. reports honoraria for an advisory board for Verity Pharmaceuticals, Orimed, and Paladin. All other authors report no potential conflicts.

                All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

                Author information
                https://orcid.org/0000-0002-4532-379X
                Article
                ciad535
                10.1093/cid/ciad535
                10954326
                37675577
                8e9abf71-6e22-4921-826d-4a50df576020
                © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 20 June 2023
                : 24 August 2023
                : 29 September 2023
                Page count
                Pages: 12
                Funding
                Funded by: Ministère de la Santé et des Services Sociaux (MSSS) du Québec;
                Funded by: Quebec’s Ministry of Health;
                Funded by: Public Health Agency of Canada, DOI 10.13039/100011094;
                Funded by: MSSS, DOI 10.13039/100013392;
                Categories
                Major Article
                COVID-19/SARS-CoV-2
                AcademicSubjects/MED00290

                Infectious disease & Microbiology
                sars-cov-2,covid-19,infectivity,recurrent infection,viral culture

                Comments

                Comment on this article